-
Kinesin Related Products (75)
Related Products (75)
-
KIF18A-IN-6
0 ImagesKIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity.
-
VLS-1272
0 ImagesSynonyms: KIF18A-IN-7VLS-1272 (Compound 22) is an orally active KIF18A inhibitor that binds to the KIF18A-microtubule complex in an ATP-noncompetitive manner (IC50 = 41 nM), blocking its ATPase activity and inhibiting microtubule translocation. This leads to abnormal accumulation of KIF18A at spindle poles, disrupting chromosome alignment and inducing mitotic arrest and apoptosis in CINHigh tumor cells (e.g., ovarian cancer OVCAR-3, breast cancer JIMT-1). VLS-1272 is a promising candidate for anti-tumor research.
-
BTB-1
0 ImagesBTB-1 is a potent, selective and reversible mitotic motor protein Kif18A inhibitor with an IC50 of 1.69 μM.
-
ALN-12115 sodium scrambled negative control
0 ImagesCat. No.: HY-177613BALN-12115 sodium scrambled negative control is the sequence scrambled negative control of ALN-12115 sodium.
-
KIF2C-IN-1
0 ImagesCat. No.: HY-173522Purity: 98.08%KIF2C-IN-1 is a cell-penetrating, selective KIF2C inhibitor with fluorescent properties (Ex/Em = 410/510 nm). KIF2C-IN-1 exhibits notable cytotoxicity and weak inhibitory effects on KIF2A/B. KIF2C-IN-1 prohibits the dissociation of KIF2C from microtubules. KIF2C-IN-1 inhibiting KIF2C reverses cross-resistance to microtubule-targeting agents. KIF2C-IN-1 reduces tumorigenesis in chemoresistant triple-negative breast cancer (TNBC) model in mice with the combination of Paclitaxel (HY-B0015).
-
AZD4877
0 ImagesAZD4877 is another isostere to Ispinesib (HY-50759)and also a kinesin spindle protein (Eg5) inhibitor with IC50 of 2 nM.AZD4877 arrests cell mitosis, leads to the formation of the monopolar spindle phenotype and induces apoptosis. AZD4877 inhibits circulating peripheral blood mononuclear cells (PBMCs) and has anti-cancer activity.
-
MC-Val-Cit-PAB-Ispinesib
0 ImagesMC-Val-Cit-PAB-Ispinesib (Compound 509) is a drug-linker conjugate for ADC, consisting of a cleavable ADC linker and Eg5 inhibitor. MC-Val-Cit-PAB-Ispinesib can be used for the synthesis of antibody-drug conjugates (ADCs).
-
GW406108X
0 ImagesSynonyms: GW108XGW406108X is a specific Kif15 (Kinesin-12) inhibitor with an IC50 of 0.82 uM in ATPase assays. GW406108X, a potent autophagy inhibitor, shows ATP competitive inhibition against ULK1 with a pIC50 of 6.37 (427 nM). GW406108X inhibits ULK1 kinase activity and blocks autophagic flux, without affecting the upstream signaling kinases mTORC1 and AMPK.
-
AM-5308
0 ImagesAM-5308 is the inhibitor for KIF18A (IC50=47 nM) that inhibits KIF18A-mediated microtubule ATPase activity. AM-5308 activates mitotic checkpoints, regulates cell division processes, including chromosome segregation and spindle assembly. AM-5308 exhibits antitumor activity.
-
SR31527 chloride
0 ImagesCat. No.: HY-118961CAS No.: 311814-78-5SR31527 chloride is a potent KIFC1 inhibitor with an IC50 value of 6.6 µM. SR31527 chloride decreases cell viability and colony formation.
-
KIF18A-IN-13
0 ImagesKIF18A-IN-13 (Compound 16) is an effective and orally active inhibitor of KIF18A with anticancer activity in vivo. KIF18A-IN-13 can be utilized for research in ovarian cancer.
-
Filanesib hydrochloride
0 ImagesSynonyms: ARRY-520 hydrochloride
-
Mitotic kinesin-IN-1 hydrochloride
0 ImagesCat. No.: HY-177246ACAS No.: 1018690-45-3Mitotic kinesin-IN-1 (Example 80) hydrochloride is a Mitotic kinesin inhibitor. Mitotic kinesin-IN-1 hydrochloride inhibits cell proliferation by suppressing mitosis. Mitotic kinesin-IN-1 hydrochloride can be used for cancer, cardiac hypertrophy, immune and inflammatory disorders, fungal infections research.
-
BRD9876
0 ImagesBRD9876 is the “rigor” inhibitor that locks kinesin-5 (Eg5) in a state with enhanced microtubules (MTs) binding, leading to bundling and stabilization of MTs. BRD9876 interacts with the tyrosine 104 residue that is part of the α4-α6 allosteric binding pocket. BRD9876 specifically targets microtubule-bound Eg5 and selectively inhibits myeloma over CD34 cells. BRD9876 has the potential for multiple myeloma (MM) research.
